New combo attack on stubborn lung cancer shows promise

This study is for people with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation). It tests if adding two chemotherapy drugs (carboplatin and pemetrexed) to the standard targeted drug osimertinib works better than taking osimertinib alone. The trial focuses on patients who still have signs of the cancer's genetic fingerprint in their blood after three weeks of initial osimertinib treatment, aiming to see if the stronger combination can better control the cancer's growth.